Intero Biosystems wants drugmakers to test on mini human intestines, not animals

Intero Biosystems is offering lab-grown human intestinal models to pharmaceutical companies as regulators encourage alternatives to animal testing. The startup is working to scale production and broaden its organoid technology for drug development use cases.

The shift toward human-derived testing models could improve how drugmakers predict safety and efficacy before clinical trials. If scalable, organ-on-a-chip and organoid platforms may become a larger part of preclinical research as regulatory pressure on animal testing increases.